Intra-Cellular Therapies ITCI 深 沪
等待开盘 07-15 09:30:00 美东时间
131.87
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 131.87
- 总市值 1411.01万
- 52周最高 131.98
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 64.09
- 委 比 0.00%
- 总股本 0.00亿
- 历史最高 131.98
- 量 比 0
- 振 幅 0.00%
- 历史最低 6.75
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多百亿美金并购新狂潮背后
原标题：百亿美金并购新狂潮背后 又一笔百亿美元级并购诞生。 7月6日，Vertex宣布以每股85美元、总价约100亿美元的全现金交易，正式将专注于内分泌罕见病...
07-08 10:19
FACTBOX-Major deals involving US drugmakers and biotechs over the past decade
FACTBOX-Major deals involving US drugmakers and biotechs over the past decade Adds details of Vertex deal in paragraphs 1 and table July 7 (Reuters) - Vertex Pharmaceuticals VRTX.O has agreed to buy Crinetics Pharmaceuticals CRNX.O for about $10 billion , expanding its reach beyond blood disorders a
07-07 18:08
FACTBOX-Major deals involving US drugmakers and biotechs over the past decade
FACTBOX-Major deals involving US drugmakers and biotechs over the past decade Adds AbbVie deal June 22 (Reuters) - AbbVie ABBV.N has agreed to buy biotech Apogee Therapeutics APGE.O for $10.9 billion in cash, as the U.S. drugmaker builds its next-generation immunology pipeline. The move adds to a gr
06-22 19:46
FACTBOX-Major deals involving US drugmakers and biotechs over the past decade
FACTBOX-Major deals involving US drugmakers and biotechs over the past decade Adds GSK deal June 9 (Reuters) - GSK GSK.L has agreed to buy cancer drug developer Nuvalent NUVL.O for $10.6 billion in its biggest deal in years, as the British drugmaker looks to bolster its pipeline and support long-ter
06-09 17:13
全球生命科学领域交易更趋谨慎
（来源：中国医药报） 转自：中国医药报 2025年，全球生命科学领域的交易活动延续低迷态势。根据IQVIA Pharma Deals公开披露的交易活动数据（下...
04-30 08:06
Johnson & Johnson publishes 2025 annual report with USD 94.2 billion sales
Johnson & Johnson publishes 2025 annual report with USD 94.2 billion sales Johnson & Johnson published its 2025 annual report, outlining increased focus on six priority areas: Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision. The company reported 5% operational sales growth in
03-11 21:23
1430亿美元，全球创新药并购重回高峰
经历2024年生科寒冬之后，2025年全球并购强势回暖，交易规模再度突破千亿美元大关，直逼2023年水平。 医药魔方MedAlpha新药投融资数据库显示，20...
01-27 16:14
JPM2026观察：超百亿巨额并购降温、AI投资热情飙升，中国药企变“台上主角”
每年年初的摩根大通全球医疗健康（JPM）大会，对于全球生物医药行业从业者而言，不只是巨头晾晒成绩单与战略蓝图的秀场，也像是决定未来一年甚至更长时间里资本流向与产...
01-26 16:12
Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301
Benitec Biopharma Inc. announced positive interim results for its BB-301 Phase 1b/2a clinical trial treating oculopharyngeal muscular dystrophy (OPMD) with dysphagia. All six patients in Cohort 1 achieved a 100% response rate, showing significant improvements in dysphagic symptoms, swallowing function, and reduced post-swallow residue. The U.S. FDA granted Fast Track designation to BB-301, recognizing the urgency of its potential for treating thi...
2025-11-03 12:10
